A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study
- Citation:
- J Clin Oncol vol 29 (suppl) abstr 7513
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- J. R. Molina G. K. Dy N. R. Foster Allen Ziegler A. A. Adjei K. M. Rowland Jr M. C. Aurby P. J. Flynn S. J. Mandrekar S. E. Schild
- Networks:
- Study
- NCCTG-N0626
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: